Stockreport

Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 [Yahoo! Finance]

Climb Bio, Inc.  (CLYM) 
PDF 2026 and initial clinical readouts for PMN, ITP and SLE in H2 2026, while healthy-volunteer data for CLYM116 is expected around midyear. Budoprutug is a CD19 monoclona [Read more]